Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PECORINO: FLOT vs XELOX in Resectable Gastric Cancer
NCT04937738Phase 2Terminated
- Sponsor
- Ukrainian Society of Clinical Oncology
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, fluorouracil, folinic acid and oxaliplatin in gastric cancer (GC) and esophagogastric junction adenocarcinoma (GEJA) (2 arms), sponsored by Ukrainian Society of Clinical Oncology. Primary endpoint: Proportion of patients who complete all the treatment per protocol up to 2 months. Started Jul 2021; status: terminated.
02
Drugs
docetaxelfluorouracilfolinic acidoxaliplatin
03
Conditions
gastric cancer (GC)esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT04937738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937738.